[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100399275":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":24,"centralContacts":37,"locations":47,"responsibleParty":71,"collaborators":24,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":24,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":24,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":50,"whyStopped":24,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"University of Chicago","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Arm","ACTIVE_COMPARATOR","60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of aspirin 81 mg.",[13],"Drug: Aspirin 81 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Arm","PLACEBO_COMPARATOR","60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of a placebo pill",[19],"Drug: Placebo",{"label":21,"type":22,"description":23,"interventionNames":24},"Observational Arm","NO_INTERVENTION","60 subjects will be placed in the observational arm. These subjects will not receive any intervention but will be followed and asked to return at the same time interval as the other 2 groups.",null,[26,33],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Aspirin 81 mg","Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.",[9],[32],"acetylsalicylic acid 81 mg",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":24},"Placebo","Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.",[15],[38,43],{"name":39,"role":40,"phone":41,"phoneExt":24,"email":42},"Sajid Shahul, MD, PhD","CONTACT","773-398-2956","sshahul1@dacc.uchicago.edu",{"name":44,"role":40,"phone":45,"phoneExt":24,"email":46},"Colleen Duncan, RN","7738342892","cduncan@bsd.uchicago.edu",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"University of Chicago Hospital","RECRUITING","Chicago","Illinois","60637","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-87.65005,41.85003,{"lat":60,"lon":59},[63,64,68],{"name":39,"role":40,"phone":41,"phoneExt":24,"email":42},{"name":65,"role":40,"phone":66,"phoneExt":24,"email":67},"John Dreixler, PhD","773-702-6700","JDreixle@dacc.uchicago.edu",{"name":69,"role":70,"phone":24,"phoneExt":24,"email":24},"Sarosh Rana, MD","SUB_INVESTIGATOR",{"type":72,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100399275","phase-4-aspirin-and-preeclampsia-100399275",false,"NCT04479072","Aspirin and Preeclampsia","Aspirin to Prevent Cardiac Dysfunction in Preeclampsia","Inclusion Criteria:\n\n1. Pregnant Adults between 18 and 45 years of age\n2. Diagnosed with preeclampsia\n3. Presenting for delivery with a singleton gestation.\n\nExclusion Criteria:\n\n1. We will exclude patients in labor\n2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation\n3. Plan to deliver outside of the participating site\n4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.\n5. Aspirin allergy\n6. Clear indication for aspirin therapy or contraindication to aspirin therapy\n7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)\n8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.\n9. Those who cannot provide consent","FEMALE","18 Years","45 Years",{"count":84,"type":85},180,"ESTIMATED","INTERVENTIONAL",[88],"PHASE4","This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.",[91],"Preeclampsia Postpartum",[93,94,95,96,97,98,99],"Preeclampsia","Postpartum GLS Levels","Postpartum Activin A Levels","Aspirin","Cardiac Postpartum Therapy","Hypertension","Cardiovascular disease","2026-04-28",{"date":102,"type":103},"2026-05-04","ACTUAL",{"date":105,"type":103},"2021-02-15",{"date":107,"type":85},"2026-12-31",{"name":5,"class":6},1]